BBOT to Showcase Two RAS-Pathway Cancer Drugs at AACR 2026
Event summary
- BBOT will present data on BBO-10203 and BBO-11818 at AACR 2026, April 17-22.
- BBO-10203 targets RAS-PI3Kα interaction in HER2+ models; oral presentation April 21.
- BBO-11818 is a pan-KRAS inhibitor in Phase 1 KONQUER-101 trial; poster April 22.
- BBO-11818 shows potent anti-tumor activity in KRAS-mutant preclinical models.
The big picture
BBOT's AACR presentations highlight its focus on RAS-pathway malignancies, an area with high unmet need. The company is competing in a crowded oncology space, where differentiation through novel mechanisms like BBO-10203's RAS-PI3Kα disruption could be key. Success in Phase 1 trials would validate its pipeline strategy against KRAS and PI3Kα-driven cancers.
What we're watching
- Clinical Validation
- Whether BBO-11818's preclinical efficacy translates to Phase 1 KONQUER-101 results.
- Competitive Positioning
- How BBOT differentiates BBO-10203's RAS-PI3Kα mechanism from existing therapies.
- Regulatory Pathway
- The pace at which BBO-10203 advances in BREAKER-101 for multiple cancer indications.
Related topics